Anti-ageing breakthroughs draw biotech investor attention — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Life expectancy has doubled over the past 150 years, with children in high-income nations having an even chance of living past 80 — yet 16–20% of those years are spent battling chronic disease in late life, per a 2018 Nature article.
- The World Health Organisation projects the global population aged 60 and over will reach 2.1 billion by 2050, with China set to lead at 500 million-plus over 60 by mid-century, intensifying healthcare cost strain.
- Carlos López-Otín, a biochemistry professor at the University of Oviedo in Spain, led the team that identified 12 "hallmarks of ageing" in 2013 and updated the framework in 2023 to reflect advances in biological sciences.
- Venki Ramakrishnan, co-winner of the 2009 Nobel Prize in Chemistry, highlights three most promising approaches: senolytics that clear senescent "zombie" cells (which stop dividing after 40–60 reproductions), stem cell regeneration and cellular reprogramming, and telomerase reactivation to lengthen chromosome ends.
- Ramakrishnan estimates it will take "at least a couple of decades" to develop successful therapeutics from these approaches.
- RBC Capital Markets senior biotechnology analyst Luca Issi says healthspan can be materially expanded sooner through better diagnostics, earlier intervention, and improved therapies — noting that genetic medicine approvals so far target rare diseases such as spinal muscular atrophy and beta-thalassemia, with cancer, cardiovascular, and eye disease treatments "around the corner."
- Issi cautions that the most exciting biotech innovations do not necessarily translate into the best investments; companies that prioritize diseases with large unmet needs and execute well-designed clinical trials are likelier winners, and competitive and regulatory landscapes matter.
Why it matters: With 2.1 billion people aged 60+ projected by 2050 — and China alone facing 500 million-plus over 60 by mid-century — healthcare cost pressures are surging globally. For biotech investors, Issi's framework favors companies that execute strong clinical trials for large unmet needs over those with the flashiest pipelines, making execution skill — not scientific novelty — the likely differentiator in this emerging theme.
Ask SkimNews
